Lee Taek Sang, Jung Ji Ye, Kim Jae Weon, Park Noh-Hyun, Song Yong-Sang, Kang Soon-Beom, Lee Hyo-Pyo
Department of Obstetrics and Gynecology and Cancer Research Institute, College of Medicine, Seoul National University, 28 Yungun-Dong, Chongno-Ku, Seoul 110-744, South Korea.
Gynecol Oncol. 2007 Jan;104(1):52-7. doi: 10.1016/j.ygyno.2006.07.003. Epub 2006 Aug 2.
Our objective was to determine the frequency of a coexisting ovarian malignancy and to evaluate the feasibility of ovarian preservation in patients with early stage endometrial carcinoma.
Endometrial cancer patients who received primary surgical treatment between 1992 and 2004 were identified using the institution's tumor registry. Information regarding patient age, preoperative and intraoperative evaluations, pathologic reports, and follow-up results was abstracted from medical records.
Coexisting ovarian malignancy was detected in 19 (7.31%) of 260 patients who underwent surgical treatment (12 metastatic and 7 synchronous primaries). The independent risk factors of a coexisting ovarian malignancy, as determined using a logistic regression model, were intraoperative extrauterine disease, non-endometrioid histology, lymph node metastasis, and patient age, and the presence of intraoperative extrauterine disease was found to most significantly predict ovarian involvement (OR=542.1; 95% CI, 57.18 to 5139.23). Seventeen of the 19 cases showed abnormal intraoperative gross findings around adnexa or other sites. Among the 206 patients without any evidence of intraoperative extrauterine disease, the coexisting ovarian malignancy rate was 0.97% (2/206), and zero for those under age of 45. In 35 patients, grossly normal ovaries were selectively saved, and no recurrence or cancer-related death occurred (median duration of follow-up: 76 months, range 3-121).
The risk of coexisting malignancy in patients without predictable risk factors is minimal. Therefore, it is possible to preserve ovaries in young women with early stage endometrial carcinoma with a thorough preoperative evaluation and extensive intraoperative exploration.
我们的目的是确定同时存在的卵巢恶性肿瘤的发生率,并评估早期子宫内膜癌患者保留卵巢的可行性。
利用该机构的肿瘤登记系统确定1992年至2004年间接受初次手术治疗的子宫内膜癌患者。从病历中提取有关患者年龄、术前和术中评估、病理报告及随访结果的信息。
在接受手术治疗的260例患者中,发现19例(7.31%)存在同时性卵巢恶性肿瘤(12例为转移性,7例为同时性原发性)。采用逻辑回归模型确定的同时性卵巢恶性肿瘤的独立危险因素为术中子宫外疾病、非子宫内膜样组织学、淋巴结转移和患者年龄,术中子宫外疾病的存在被发现最能显著预测卵巢受累(OR=542.1;95%CI,57.18至5139.23)。19例中有17例术中附件或其他部位有异常大体表现。在206例无术中子宫外疾病证据的患者中,同时性卵巢恶性肿瘤发生率为0.97%(2/206),45岁以下患者为零。35例患者中,选择性保留了大体正常的卵巢,未发生复发或癌症相关死亡(中位随访时间:76个月,范围3-121个月)。
无可预测危险因素的患者同时存在恶性肿瘤的风险极小。因此,通过全面的术前评估和广泛的术中探查,对早期子宫内膜癌的年轻女性保留卵巢是可行的。